↓ Skip to main content

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, March 2023
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
6 X users

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma
Published in
Journal of Experimental & Clinical Cancer Research, March 2023
DOI 10.1186/s13046-023-02633-0
Pubmed ID
Authors

Francesca Scionti, Giada Juli, Roberta Rocca, Nicoletta Polerà, Matteo Nadai, Katia Grillone, Daniele Caracciolo, Caterina Riillo, Emanuela Altomare, Serena Ascrizzi, Basilio Caparello, Maria Cerra, Mariamena Arbitrio, Sara N. Richter, Anna Artese, Stefano Alcaro, Pierosandro Tagliaferri, Pierfrancesco Tassone, Maria Teresa Di Martino

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by high genomic instability, and telomere dysfunction is an important cause of acquired genomic alterations. Telomeric repeat-containing RNA (TERRA) transcripts are long non-coding RNAs involved in telomere stability through the interaction with shelterin complex. Dysregulation of TERRAs has been reported across several cancer types. We recently identified a small molecule, hit 17, which stabilizes the secondary structure of TERRA. In this study, we investigated in vitro and in vivo anti-MM activities of hit 17. Anti-proliferative activity of hit 17 was evaluated in different MM cell lines by cell proliferation assay, and the apoptotic process was analyzed by flow cytometry. Gene and protein expressions were detected by RT-qPCR and western blotting, respectively. Microarray analysis was used to analyze the transcriptome profile. The effect of hit 17 on telomeric structure was evaluated by chromatin immunoprecipitation. Further evaluation in vivo was proceeded upon NCI-H929 and AMO-1 xenograft models. TERRA G4 stabilization induced in vitro dissociation of telomeric repeat-binding factor 2 (TRF2) from telomeres leading to the activation of ATM-dependent DNA damage response, cell cycle arrest, proliferation block, and apoptotic death in MM cell lines. In addition, up-regulation of TERRA transcription was observed upon DNA damage and TRF2 loss. Transcriptome analysis followed by gene set enrichment analysis (GSEA) confirmed the involvement of the above-mentioned processes and other pathways such as E2F, MYC, oxidative phosphorylation, and DNA repair genes as early events following hit 17-induced TERRA stabilization. Moreover, hit 17 exerted anti-tumor activity against MM xenograft models. Our findings provide evidence that targeting TERRA by hit 17 could represent a promising strategy for a novel therapeutic approach to MM.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 20%
Student > Postgraduate 2 13%
Student > Ph. D. Student 1 7%
Unspecified 1 7%
Unknown 8 53%
Readers by discipline Count As %
Agricultural and Biological Sciences 2 13%
Chemistry 2 13%
Biochemistry, Genetics and Molecular Biology 1 7%
Unspecified 1 7%
Medicine and Dentistry 1 7%
Other 0 0%
Unknown 8 53%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2023.
All research outputs
#7,914,810
of 25,728,350 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#505
of 2,429 outputs
Outputs of similar age
#136,855
of 424,268 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#12
of 55 outputs
Altmetric has tracked 25,728,350 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,429 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,268 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.